Pear Therapeutics

Showing 4 posts of 4 posts found.


FDA approves first prescription mobile app for opioid use disorder, courtesy of Sandoz and Pear Therapeutics

December 11, 2018
Manufacturing and Production, Sales and Marketing FDA, Novartis, Pear Therapeutics, app, opioid crisis, opioid epidemic, opioids, pharma, reSET-o

A digital therapeutic launched by Pear Therapeutics and Novartis’ generics and biosimilars division Sandoz has become the first FDA-approved app …


Novartis expands Pear partnership to tackle opioid and substance use disorder

April 23, 2018
Research and Development, Sales and Marketing Novartis, Pear Therapeutics, Sandoz, opioids, pharma, substance use disorder

Novartis has announced that it will expand its current partnership with Pear Therapeutics, signed in March, as it reveals that …


Novartis forms a Pear to develop mobile therapies

March 2, 2018
Medical Communications, Research and Development Novartis, Pear Therapeutics, biotech, drugs, pharma, pharmaceutical

Novartis has announced an agreement between Pear Therapeutics and itself to develop two digital therapeutics, one in schizophrenia and one …


FDA approves first medical app, for use in addiction

September 18, 2017
Sales and Marketing Pear Therapeutics, biotech, drugs, pharma, pharmaceutical, reset

The FDA has taken a major step in the digitisation of healthcare by handing out the first medical app approval: …

Latest content